Mavacamten
Treatment for Hypertrophic Cardiomyopathy
Typical Dosage: 5-15mg once daily
Effectiveness
85%
Safety Score
65%
Clinical Trials
31
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5-15mg once daily
Time to Effect
Weeks to 3 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
14(Treat 14 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$102,000
Monitoring:$2,000
Side Effect Mgmt:$200
Total Annual:$104,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
4
Outcome-Based Costs
Cost per Responder
$130,250
Comparison vs Standard of Care (Beta-blockers/CCBs + Disopyramide)
Cost Difference
+$100,000/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
11 active trials recruiting for Mavacamten in Hypertrophic Cardiomyopathy
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
NCT07361289RECRUITING
500 participants
OBSERVATIONAL
Beijing, China +14 more
Started: Jan 15, 2026
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743ACTIVE NOT RECRUITINGPHASE4
63 participants
INTERVENTIONAL
West Hollywood, United States +22 more
Started: Jan 24, 2024
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
NCT06549608ACTIVE NOT RECRUITING
685 participants
OBSERVATIONAL
Vancouver, Canada
Started: Apr 20, 2024
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221ACTIVE NOT RECRUITINGPHASE3
44 participants
INTERVENTIONAL
Birmingham, United States +46 more
Started: Apr 17, 2024
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06146660RECRUITING
600 participants
OBSERVATIONAL
Seoul, South Korea +1 more
Started: Jul 24, 2024
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
NCT06947590ACTIVE NOT RECRUITINGNA
78 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 20, 2025
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129RECRUITING
118 participants
OBSERVATIONAL
Boston, United States
Started: May 10, 2024
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
NCT06023186RECRUITING
20 participants
OBSERVATIONAL
Charlottesville, United States
Started: Nov 3, 2023
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
NCT07383025RECRUITING
200 participants
OBSERVATIONAL
Tokyo, Japan
Started: May 21, 2025
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
NCT07557498RECRUITING
362 participants
OBSERVATIONAL
Bollington, United Kingdom
Started: Jan 15, 2026
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
NCT07541833RECRUITING
36 participants
OBSERVATIONAL
Kochi, Japan
Started: Feb 5, 2026
Completed Clinical Trials
9 completed trials for Mavacamten in Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
NCT05135871COMPLETEDPHASE1
45 participants
INTERVENTIONAL
Shanghai, China
Started: Oct 31, 2021
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07529938COMPLETED
222 participants
OBSERVATIONAL
Zhengzhou, China
Started: Jan 1, 2024
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03496168COMPLETEDPHASE2
13 participants
INTERVENTIONAL
Scottsdale, United States +3 more
Started: Apr 26, 2018
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
NCT05582395COMPLETEDPHASE3
580 participants
INTERVENTIONAL
Birmingham, United States +223 more
Started: Dec 14, 2022
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
NCT03723655COMPLETEDPHASE2, PHASE3
314 participants
INTERVENTIONAL
Scottsdale, United States +67 more
Started: Sep 27, 2018
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT05414175COMPLETEDPHASE3
38 participants
INTERVENTIONAL
Uwajima, Japan +19 more
Started: Aug 19, 2022
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT07168655COMPLETED
163 participants
OBSERVATIONAL
Philadelphia, United States
Started: Feb 21, 2023
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05174416COMPLETEDPHASE3
81 participants
INTERVENTIONAL
Beijing, China
Started: Jan 4, 2022
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT03470545COMPLETEDPHASE3
251 participants
INTERVENTIONAL
Scottsdale, United States +70 more
Started: May 29, 2018
Showing 20 of 38 total trials